Tidal Wave Auto Spa Announces 17th Annual Charity Day on Friday, September 19th
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Michelle Stoughton Named President of Anthem Blue Cross and Blue Shield Medicaid in Ohio
COLUMBUS, Ohio--(BUSINESS WIRE)--Anthem Blue Cross and Blue Shield (Anthem), a leading provider of health benefits for Ohio residents enrolled in the state's Medicaid managed care program, announced today that Michelle Stoughton has been named president of its Medicaid health plan. 'Michelle is a highly respected leader with extensive experience in healthcare policy and government,' said Jennie Reynolds, east region president of Anthem Medicaid. 'Her proven track record in Ohio and her dedication to community health make her exceptionally well-suited to lead our Medicaid operations in the state. We are confident in Michelle's ability to drive innovation, foster strong partnerships, and improve the whole health of the Ohioans we serve.' In her new role, Stoughton assumes responsibility for all aspects of Anthem's Medicaid health plan operations in Ohio, ensuring its more than 200,000 members receive access to innovative, high-quality healthcare and support services. She will also lead efforts to strengthen relationships in the community with state leaders, providers, and other key stakeholders. Starting in 2026, Anthem will be one of four managed care organizations to provide services to Ohioans who are dually eligible for both Medicare and Medicaid healthcare coverage under its Next Generation MyCare Ohio program, in addition to continuing to provide benefits through the managed care program. 'Anthem's long-standing commitment to improving the health of Ohio communities is one I deeply share, and I'm honored to take on this leadership role,' said Stoughton. 'I look forward to working alongside our state partners, providers, members, and local organizations to strengthen access to high-quality care—both today and as we prepare to support some of Ohio's most vulnerable individuals in the Next Generation MyCare Ohio program beginning in 2026. Together, we'll continue to serve with compassion, elevate health outcomes, and make a meaningful impact in the lives of Ohioans across the state.' Stoughton brings nearly 15 years of experience in healthcare policy to her new role. She most recently served as the regional vice president of government relations for Anthem in Ohio and managed the central region team of senior government relations directors for Anthem's parent company. Before that, Stoughton served as the Midwest director for Albers & Company and as government relations director for the Ohio Council of Retail Merchants. She has also served as a legislative aide in the Ohio House of Representatives. Stoughton holds a bachelor's degree from Miami University and a Master of Public Administration from The Ohio State University. She volunteers as coordinator of All Saints Episcopal Church's In the Garden Program, a meal service for homeless individuals in downtown Columbus. About Anthem Blue Cross and Blue Shield in Ohio Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company, an independent licensee of the Blue Cross Blue Shield Association. ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Additional information about Anthem Blue Cross and Blue Shield in Ohio is available at Also, follow us on LinkedIn, Facebook, and X at @AnthemBCBS.
Newsweek
an hour ago
- Newsweek
Democrats' Chances of Flipping Joni Ernst's GOP Senate Seat in Iowa—Polls
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Democrat Jackie Norris jumped into the Iowa Senate race to challenge GOP Senator Joni Ernst on Tuesday in a race Democrats are hoping they can make competitive next November. Bryan Kraber, Ernst's campaign manager, told Newsweek Iowans will "reject this Obama-era bureaucrat" in a statement responding to Norris' candidacy. Newsweek also reached out to Norris' campaign for comment via email. Why It Matters Democrats are facing a challenging Senate map ahead of the midterms, despite hopes that President Donald Trump's diminishing approval rating could fuel a 2018-style "blue wave" across the country. The party has to turn to states like Iowa, a former battleground that has shifted rightward over the past decade, as potential flip opportunities if they have any hope of taking back control of the upper chamber. Iowa has not elected a Democratic senator since 2008 and backed Trump in each of his three presidential bids—including by 13 points last November, an indication of how Republican the state has become. Nonetheless, Democrats remain hopeful that a strong national environment, as well as backlash over Ernst's recent Medicaid comments, can make the race more competitive than expected. Iowa Senator Joni Ernst speaks during The Hill & Valley Forum 2025 at The U.S. Capitol Visitor Center on April 30, 2025, in Washington. Iowa Senator Joni Ernst speaks during The Hill & Valley Forum 2025 at The U.S. Capitol Visitor Center on April 30, 2025, in 137 Ventures/Founders Fund/Jacob Helberg What To Know Norris emphasized her experience as a teacher and school board member in a video announcing her candidacy released on Tuesday. "As a teacher and a school board member, you see the invisible burdens families are carrying," she said. "Take the Medicaid cuts. Who is it impacting? Middle class families right now, they can't afford to put food on the table. We have to find a way to make things more affordable for families." Early polls of the race suggest Ernst will have an advantage in Iowa. A Public Policy Polling survey found that Ernst would lead a generic Democrat by about two percentage points—45 percent to 43 percent, with 12 percent still unsure. However, the poll did not ask voters about specific Democratic candidates. The survey of 568 Iowa voters was taken from June 2 to June 3. A Data for Progress poll from May found that Ernst would have a lead over most Democratic candidates on an informed ballot. When asked about Norris, voters preferred Ernst by about six points (50 percent to 44 percent). Democrat Nathan Sage fared better, leading Ernst by about two points (47 percent to 45 percent). Ernst also led State Representative J.D. Scholten by six points (49 percent to 43 percent) and State Senator Zach Wahls by 10 points (52 percent to 42 percent). The poll surveyed 779 likely voters from May 7 to May 12. Republicans are favored to hold the Iowa Senate seat, according to Kalshi betting odds, which give the GOP a 74 percent chance and Democrats a 26 percent chance of winning next November. Outside of Iowa, Democrats view the Maine seat held by Senator Susan Collins and the open North Carolina seat as their best opportunities to pickup a win in a GOP-held seat next November. Maine backed former Vice President Kamala Harris by about seven points, while North Carolina backed Trump by about three points last November. Republicans currently have a 53-47 majority, so Democrats need to win multiple double-digit Trump states like Iowa, Ohio or Texas to win back control of the Senate. Democrats are also defending seats in Georgia and Michigan, both of which backed Trump last year. What People Are Saying Bryan Kraber told Newsweek: "Our state is ruby red because Iowans reject higher taxes, open borders, and woke ideology, just like they will reject this Obama-era bureaucrat" Democratic hopeful Jackie Norris wrote in a press release: "Red versus blue isn't fixing anything. Iowa needs a Senator who doesn't just talk tough but rolls up their sleeves, and has the grit and experience to actually get something done." Sabato Crystal Ball forecasters J. Miles Coleman and Kyle Kondik wrote in a June update: "In 2014, [Ernst] won as part of a broader GOP wave—and she got help from a gaffe-prone opponent. Six years later, she won reelection as Trump was carrying Iowa by a strong margin (Ernst ran a little bit behind Trump). It's possible that 2026 could be like 2018: Iowa did not have a Senate election that year, but Democrats did end up winning three of the state's four U.S. House seats that year, and we suspect that if Iowa had had a Senate election, it likely at least would have been close." What Happens Next Ernst has not confirmed her plans for the 2026 election. Both the Cook Political Report and Sabato's Crystal Ball consider the race to be Likely Republican.
The Star
an hour ago
- The Star
Pfizer reports strong Q2 revenue
NEW YORK, Aug. 5 (Xinhua) -- U.S. pharmaceutical company Pfizer announced its second-quarter earnings on Tuesday, reporting a 10 percent year over year operational growth. The financial results posted by the New York-headquartered company represent revenue of 14.7 billion U.S. dollars or 0.51 dollars of earnings per share. In an upward revision of its full-year guidance, Pfizer said it now expects adjusted earnings per share for 2025 to range between 2.90 dollars and 3.10 dollars, compared to its previous forecast of 2.80 dollars to 3.00 dollars. The company maintained its annual revenue projection of 61 billion to 64 billion dollars, reflecting confidence in its underlying business performance. "Our business is performing well and I'm pleased with the progress we achieved in the second quarter," Pfizer Chairman and CEO Albert Bourla said in a statement. Pfizer's strong performance came amid mounting policy pressures from the White House. U.S. President Donald Trump has recently sent letters to 17 pharmaceutical companies, including Pfizer, demanding that they cut prices on all existing medications for Medicaid patients to levels no higher than those in Europe. During Tuesday's earnings call, Bourla acknowledged that the company received the letter from the Trump administration. However, he declined to elaborate on the policy's specific impacts, although he emphasized that discussions with the administration have been "extremely productive." Pfizer's Q2 results were bolstered by rising sales in several key product categories. Its Vyndaqel line of cardiomyopathy treatments showed solid growth, and COVID-19-related products were major contributors.
